Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527212 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease
A Phase 3 study, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT03527212: Completed Phase 3 study, sponsored by Senju Pharmaceutical Co..
NCT03527212 is a Phase 3 study that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 329 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03527212, a Phase 3 study, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
Primary Outcome
Number of patients showing complete clearing of corneal fluorescein staining, scored on the Baylor grading system.
Interventions
- DRUG Placebo
- DRUG SJP-0035 0.001%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 3 |
What the finished NCT03527212 record still lists
NCT03527212 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03527212 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03527212 about?
NCT03527212 is a clinical study titled "A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease". A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
What is the current status of trial NCT03527212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2018-08-20. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03527212?
The interventions under investigation include: Placebo (DRUG), SJP-0035 0.001% (DRUG).
Who is sponsoring clinical trial NCT03527212?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03527212's enrollment target sits among peer trials
329 1074th of 2000 higher than 927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI